10-Q quarterly report · filed Nov 12, 2026

CorMedix Inc. (CRMD) Q3 2026 10-Q Quarterly Report

Short answer

CorMedix Inc. (CRMD) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (down 47.7% year over year) with net income of −$15M.

Q3 2026 key financials · XBRL

Revenue
$55M
−47.7% YoY · −46.5% QoQ
Net income
−$15M
−113.6% YoY · −156.6% QoQ
Operating margin
-12.1%
Gross margin
55.0%
EPS (diluted)
−$0.15
−110.8% YoY · −151.7% QoQ

Source: XBRL data from the CorMedix Inc. (CRMD) Q3 2026 10-Q on SEC EDGAR. USD.

CorMedix Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $54.5M, down 48% YoY from $104.3M, driven by lower DefenCath net pricing
  • Gross margin 55.0% vs 89.3% YoY, with net income $14.7M loss vs $108.6M income
  • DefenCath worst performer, product sales $17.2M vs $88.8M; Melinta Portfolio sales $31.4M vs $12.8M
  • Cash and investments $355.2M vs $148.5M at December 31, 2025; operating cash flow $218.3M year to date
  • CMS reimbursement headwind: $8.32 add-on effective January 2027, expected 2027 average at least twice $2.37 current rate

Risk Factors

  • Acquisition risk: Heron transaction may fail closing conditions or stockholder vote, pressuring share price and results
  • Regulatory risk: CMS post-TDAPA adjustment reduced DefenCath net pricing in 2H 2026
  • Reimbursement risk: Quarterly CMS calculations begin in 2027, increasing DefenCath revenue volatility
  • Financial risk: Proposed $150 million senior secured term loan would increase interest costs and repayment obligations
  • Dilution risk: Heron would receive 14,583,333 shares, representing approximately 18.3% pro forma ownership

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CorMedix Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.